One of those parents, Meritor Transmission, is itself a subsidiary of Meritor Inc. (MTOR).
FORBES: Antitrust Consensus Shifting As Courts Weigh Impact Of Monopolists And Predators
In many cases MTOR drugs don't shrink tumors much but merely blunt their growth.
Some researchers worried an mTOR drug would suppress patients' immune systems, as Rapamune does by design.
Afinitor, Torisel and other MTOR drugs are the product of a four-decade research odyssey.
Then her husband read something on the Internet about a trial of Novartis' mTOR drug.
Drug companies think they may discover more uses for MTOR blockers by combining them with other drugs.
He says mTOR may be a key resistance mechanism that cells use to evade the effects of Herceptin.
If you're a cancer you need to get bigger and bigger, to make more cells, you use mTOR.
Experiments in simpler organisms like worms and yeast have also seemed to implicate mTOR in the aging process.
One possibility is that mTOR is turned on by starvation--which is another way to extend life in mice.
It blocks a signaling pathway called mTOR that appears to play a role in proliferation of several cancers.
But in 2001 Clackson and his group started synthesizing an mTOR cancer drug that would sidestep the immune system.
Other competitors in the consumer cyclical sector include: Dana Holding Corporation (DAN), Meritor (MTOR), and Enova Systems, Inc. (ENA).
Wyeth's MTOR drug Torisel was approved in 2007 for certain kidney tumors.
In 2004 scientists at Johns Hopkins discovered that a second protein linked to MTOR is frequently mutated in colon, stomach and brain tumors.
When he started studying MTOR 15 years ago, it was so obscure that colleagues asked him why he bothered to work on it.
Researchers at Wyeth and elsewhere are working on second-generation versions of the drugs, which more directly block MTOR and could be more potent.
The drug, which hits a key growth-promoting molecule inside cells, called mTOR, is also showing surprising preliminary promise in treating advanced breast cancer patients.
The drug works by hitting a key growth-promoting node involved in cell growth called mTOR that may go out of control in neuroendocrine cancers.
In 2001 researchers at Columbia University and ucla showed in mouse experiments that MTOR drugs compensated for the loss of a protein mutated in prostate and brain cancers.
Unwanted side effects on the immune system could still emerge as a problem in Ariad's trials, but early data provide hope that mTOR drugs could attack other cancers as well.
The pill blocks a crucial growth-promoting protein called mTOR.
The Novartis drug suppresses a protein called MTOR (mammalian target of rapamycin), which receives incoming growth signals from the surface of the cell and directs them to grow fatter, a necessary step before cell division.
Harrison says that he hopes that data from studies of humans taking mTOR drugs might also provide clues, although they may be difficult to tease out: Patients with cancer or those undergoing transplant, the people who get mTOR drugs now, don't tend to die of old age.
The active ingredient in Rapamune, rapamycin, was discovered decades ago but scientists didn't understand how the drug worked until a graduate student named David Sabatini discovered the mammalian target of rapamycin (mTOR), a protein that acts as part of a complicated set of chemical signals that causes cells to divide.
应用推荐